ISMP
ISMP ISMP
 
     
 
ISMP
Ambulatory pump safety: Managing home infusion patients admitted to the ED and hospital
September 10, 2015

Before the 1980s, patients had to be hospitalized to receive various types of infusion therapies to treat diseases unresponsive to oral medications. Since then, the availability of lightweight ambulatory pumps has made infusion therapy possible in alternative settings outside the hospital, including in the home. A new market research study suggests that the use of ambulatory pumps is commonplace and will continue to grow at an annual rate of about 9% over the next 5 years.1

This growth is tied to an increasing geriatric population, expanding prevalence of chronic diseases such as cancer and diabetes, and positive patient outcomes in a less expensive home setting. Ongoing technology developments and newer applications of ambulatory pumps in the home are further driving an increase in their use. Today, ambulatory pumps are being used to deliver various medications (Table 1) to treat a wide array of diseases and conditions, from diabetes to chronic pain. This mode of delivery typically involves using a needle or catheter under the skin to administer medications, blood products, nutrition, or hydrating solutions via the intravenous, subcutaneous, epidural/intrathecal, percutaneous, intrawound, intrahepatic, or other parenteral routes.

As with any medication delivery system, patient safety can be jeopardized if the devices are mishandled when filling, programming, attaching, and monitoring the pumps. The ambulatory pump marketplace is diverse, so the devices rarely have standard components. This poses a unique challenge for healthcare providers when patients using these devices are admitted to an emergency department (ED) or hospital. Often, healthcare providers are not familiar with all the ambulatory pumps in use, and most patients who use these devices are ill informed, leading to serious errors—the most dangerous of which is overinfusion. For example, just recently in our June 18, 2015 newsletter, we described numerous overinfusions of fluorouracil caused by misprogramming a CADD ambulatory infusion pump and misusing a rate-specific elastomeric EASYPUMP. In our November 20, 2014 newsletter, we published an event in which both a patient and clinicians in the ED mistakenly believed an elastomeric DOSI-FUSER pump had malfunctioned and delivered an overinfusion of fluorouracil when it had not, leading to the omission of a large portion of the prescribed chemotherapy after the infusion was disconnected prematurely.    

Insulin pumps provide another example of a unique challenge to clinicians when patients with these devices present for treatment. Insulin pumps have been used for more than 35 years. There are nearly a dozen different devices available in the US today. In 2007, about 374,000 patients with type 1 diabetes were using insulin pumps.2 Today, more than half a million patients with type 1 and type 2 diabetes are using insulin pumps.3,4 Yet, few healthcare clinicians working in hospitals have a comprehensive understanding of these devices. When patients with insulin pumps are evaluated in the ED or admitted to the hospital, they typically have more knowledge and expertise with using the pump for insulin delivery than the medical professionals who are handling their care.1

So, what happens in your hospital when a patient using an ambulatory pump to deliver a medication or solution is admitted to the ED or hospital? What if the patient is unresponsive and cannot help identify the medical device found at his or her waist? Simply discontinuing the therapy may NOT be the most clinically appropriate or safest solution. Turning off the ambulatory pump without understanding its purpose and contents could lead to serious, even fatal, events.5 For example, in a 2014 consensus statement, the American Association of Clinical Endocrinologists and the American College of Endocrinology encourage hospitalized patients and their admitting physicians to not discontinue an insulin pump, but rather to consult the specialist responsible for the patient’s insulin pump management if the patient cannot manage his or her own pump.4 Another example includes the serious consequences of interrupting a continuous infusion of an IV prostacyclin (epoprostenol or treprostinil) used to treat pulmonary hypertension. 

But continuing the infusion without knowing how to manage the pump may not be a clinically appropriate or safe alternative either, especially if the patient is not well enough to assist with managing the device. Even allowing a very capable patient to manage his or her own ambulatory medication pump can be risky.5 For example, it may be impossible to determine if the device is working properly or where to find replacement parts or batteries if clinicians don’t know how to operate that particular pump. Clinicians may not know how to turn off the pump in an emergency or refill the device when it is empty.6 Serious errors are possible. With insulin pumps, for example, errors have been reported in which a patient self-administered a dose of insulin via an ambulatory pump without telling the nurse, and the nurse administered the same dose via an injection. Also, if the patient’s condition changes or they must undergo surgery, the ambulatory pump may need to be managed by clinicians or turned off temporarily.5 

ISMP is interested in learning how hospitals are handling patients who arrive for treatment with an external ambulatory pump, with a goal of publishing guidelines associated with this situation. We have prepared a short survey to learn about your practices, concerns, and patient outcomes. We encourage all US hospitals to participate in this important survey. See page 4 (in the PDF version) for the survey, which can be accessed at: www.ismp.org/sc?id=612. We would appreciate your online responses by October 30, 2015.  

 

References

  1. Global home infusion therapy market will reach a valuation of US$27 billion by 2020: Persistence Market Research [news release]. New York, NY: Marketers Media; July 24, 2015. www.ismp.org/sc?id=607
  2. Bruttomesso D, Costa S, Baritussio A. Continuous subcutaneous insulin infusion (CSII) 30 years later: Still the best option for insulin therapy. Diabetes Metab Res Rev. 2009;25(2):99-111.
  3. Chait J. Insulin pumps: Not just for type 1. Diabetes Self-Management. Published August 31, 2006. Updated June 20, 2014. www.ismp.org/sc?id=608
  4. Grunberger G, Abelseth JM, Bailey TS, et al. Consensus statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. Endocr Pract. 2014;20(5):463-89. www.aace.com/files/insulin-pump-management-cs.pdf
  5. Healthcare Technology Foundation, ECRI Institute. Home infusion: A safety guide for patients and caregivers. 2013.
  6.  Carson SL. Patient-supplied medication infusion devices in the emergency department: Are you ready? J Emerg Nurs. 2012;38(3):267-9.
Resources
Acute Care Main Page
Current Issue
Past Issues
Highlighted articles
Action Agendas
  - Free Nursing CEs
Special Alerts
Group Purchasing Subscription
Subscribe
Newsletter Editions
Acute Care
Community/Ambulatory Care
Nurse AdviseERR
Long-Term Care AdviseERR
Safe Medicine
Home | Contact UsEmployment  |   Legal Notices | Privacy Policy | Help Support ISMP
 Med-ERRS | Medication Safety Officer Society Medication Safety Officers Society | Consumer Medication Safety For consumers
ISMP Canada | ISMP Spain  | ISMP Brasil  | International Group  | Pennsylvania Patient Safety Authority

200 Lakeside Drive, Suite 200, Horsham, PA 19044, Phone: (215) 947-7797,  Fax: (215) 914-1492
© 2017 Institute for Safe Medication Practices. All rights reserved

ISMP
ISMP